The clinical relevance of these combinations is underscored by promising outcomes in trials involving HER2-positive breast cancer patients, where dual-targeting therapies have outperformed monotherapies in progression-free survival and response rates [70,71]. This evidence concerns the gene ERBB2 and breast carcinoma.